Immune evasion is a hallmark feature of cancer, and it plays an important role in tumour initiation and progression. In addition, tumour immune evasion severely hampers the desired antitumour effect in multiple cancers. In this study, we aimed to investigate the role of the Notch pathway in immune evasion in the head and neck squamous cell carcinoma (HNSCC) microenvironment. We first demonstrated that Notch1 signaling was activated in a Tgfbr1/Pten-knockout HNSCC mouse model. Notch signaling inhibition using a c-secretase inhibitor (GSI-IX, DAPT) decreased tumour burden in the mouse model after prophylactic treatment. In addition, flow cytometry analysis indicated that Notch signaling inhibition reduced the sub-population of myeloid-derived suppressor cells (MDSCs), tumour-associated macrophages (TAMs) and regulatory T cells (Tregs) , as well as immune checkpoint molecules (PD1, CTLA4, TIM3 and LAG3), in the circulation and in the tumour. Immunohistochemistry (IHC) of human HNSCC tissues demonstrated that elevation of the Notch1 downstream target HES1 was correlated with MDSC, TAM and Treg markers and with immune checkpoint molecules. These results suggest that modulating the Notch signaling pathway may decrease MDSCs, TAMs, Tregs and immune checkpoint molecules in HNSCC.
Immune evasion is a hallmark feature of tumours as they employ various strategies to suppress the immune system's ability to recognize and destroy cancer cells. 1 Accumulating evidence of the antitumour activity of the immune system supports recent success in cancer immunotherapy. 2 Many immune cells play a central role in immune evasion in the head and neck squamous cell carcinoma (HNSCC) tumour microenvironment; for example, the presence of myeloidderived suppressor cells (MDSCs), immunosuppressive regulatory T cells (Tregs) and tumour-associated macrophages (TAMs) is imbalanced and enhanced in HNSCC. 3 MDSCs represent heterogeneous immunosuppressive cells in multiple cancer types, dampening T cell-mediated immune surveillance, attenuating the cytotoxicity of NK cells and supporting stem cell-like cancer cells. 4, 5 MDSCs have been recognized in mice by the expression of CD11b and Gr-1 (Ly6C 1 /Ly6G 1 ), and subpopulations of MDSCs have been shown to exist: polymorphonuclear (PMN)-and monocytic (M)-MDSCs. 6 The PMN-MDSCs were defined as CD11b (Tregs) play an important role in regulating the immune system by suppressing self-reactive T cells during excessive immune response in peripheral lymphoid tissues. 7 TAMs secrete an array of cytokines and deplete L-arginine in the tumour microenvironment to suppress T cell activity. 8, 9 Given these immunosuppressive effects, it has been proposed that elimination of these immature myeloid cells and Tregs may significantly improve antitumour responses and enhance the beneficial effects of cancer immunotherapy. 10, 11 Immune checkpoint blockade antibodies enhance T cell anti-tumour activity and have produced exciting and consistently encouraging results in the treatment of various cancers, including head and neck cancer. 7 Tumours co-opt certain immune-checkpoint pathways such as programmed cell death protein 1 (PD1), cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), T cell membrane protein 3 (TIM3) and lymphocyte activation gene 3 (LAG3) as a major mechanism of immune resistance, particularly against T cells that are specific for tumour antigens. 12 Increased expression of immune checkpoint proteins on T cells may reflect an exhausted or anergic state. Notch1 signaling plays a fundamental role in the implementation of differentiation and proliferation in the regulation of self-renewal programs in development and disease. [13] [14] [15] Accumulating evidence suggests that excessive activation of the Notch1 signaling is implicated in a variety of tumours, particularly in leukemia and HNSCC. 16 Activating mutations of Notch1 signaling are found in approximately 50% of Chinese HNSCC patients 16, 17 and only 10% of Caucasian patients. 18, 19 Our previous study indicated that activation of the Notch1 pathway plays a pivotal role in cancer stem-like cell maintenance in HNSCC, participating in epithelial-mesenchymal transition (EMT) and increasing chemoresistance. 20 Several reports have suggested that the Notch1 signaling pathway plays vital roles in T cell expansion and Treg induction. 21 However, the exact role of Notch1 signaling in myeloid cell expansion and immune tolerance is rather controversial. 22, 23 In addition, the comprehensive effect of the Notch1 signaling pathway in cancer cells and immune cells in the solid tumour microenvironment remains unclear.
This study was designed to investigate the precise role of Notch1 signaling in the modulation of tumour-infiltrating MDSCs, TAMs, Tregs and immune checkpoint molecules in HNSCC.
Material and Methods

Immunocompetent transgenic HNSCC mouse models
All experiments were conducted in accordance with guidelines of the Institutional Animal Care and Use Committee of the Wuhan University, Wuhan, China. The time inducible tissuespecific Tgfbr1/Pten double knockout mice (K14-Cre ERtam 6; , Tgfbr1/Pten 2cKO) were maintained and genotyped according to published protocols. 24, 25 All animal studies were carried out in compliance with the NIH guidelines for the use of laboratory animals in pathogen free ASBL3 animal center of the Wuhan University and approved by the Animal Care and Use Committee of the Wuhan University (2014LUNSHENZI06, 2016LUNSHENZI62). All the mice were in FVBN/CD1/129/C57 mixed background.
Drugs and DAPT treatment
The g-secretase inhibitor DAPT (N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-S-phenylglycinet-Butyl Ester, GSI-IX), purchased from Selleck Chemicals (Houston, TX), was initially dissolved in 100% ethanol at a concentration of 20 mg/ml, and the aliquots were stored at-208C. The working solution was further diluted in PBS at a final concentration of 2 mg/ ml immediately before use. The vehicle was used as a negative control. The 10-to 12-week-old Tgfbr1/Pten 2cKO mice (Tgfbr1 flox/flox ; Pten flox/flox ; CK14-Cre ERtam 6) were orally gavaged with tamoxifen (200 ll of a 10 lg/ll solution in corn oil) for 5 consecutive days as previously described. 24 For the chemopreventive experiment, the Tgfbr1/Pten 2cKO mice were randomly divided into a control group (vehicle, i.p. daily, n 5 7 mice) and a DAPT treatment Group (10 mg/kg, i.p. daily, n 5 9 mice) on Day 21. Mice were treated with either DAPT or vehicle for 3 weeks. Tumour size was measured with a micrometre calliper, and tumours were photographed every other day. The mice were euthanized at the end of the studies, and tissues were harvested for flow cytometry, Western blot and immunohistochemical analysis.
Flow cytometry
A single cell suspension was prepared from the spleen, draining lymph nodes (DLNs), blood and tumours of the HNSCC mouse models as previously described. 26 Specifically, the tumour tissues and immune organs were harvested and processed with a gentle Macs dissociator and a mouse tumour dissociation kit (Miltenyi Biotec, Germany). Flow cytometry was performed with a FACS Caliber flow cytometer equipped with CellQuest software (Becton Dickinson, Mountain View, CA). The following anti-mouse antibodies were used for staining: FITC-conjugated anti-CD3, anti-CD4, anti-CD11b, PE-conjugated anti-Ly6G, anti-PD1, anti-TIM3, anti-LAG3, anti-CTLA4, anti-IFN-g, PE-Cy7-conjugated anti-Ly6C, Percp-Cy5.5-conjugated anti-F4/80, anti-CD8 and mouse regulatory T cell staining kit #3 (all from eBioscience, San Diego, CA), as well as isotype-matched IgG controls (eBioscience, San Diego, CA). All the antibodies were used following the manufacturer's recommended protocols. The cells were analyzed using FlowJo (Tree Star, Ashland, OR) and gated by the side scatter and forward scatter filters. Nonviable cells were excluded by staining with 7AAD (Invitrogen). 1 T cells were stained with CFSE, and then were stimulated with 25 lg/ml aCD3, 2.5 lg/ml aCD28 and 30 IU/ml rIL-2 (BD Pharmingen TM ). The activated T cells were, respectively, cocultured with MDSCs, TAMs, and Tregs at ration of 1:1, 1:0.5, and 1:0.25 in 96-well round-bottom plate. 72 hrs later, cells were harvested for CFSE analysis by flow cytometry.
Proliferation assay
Western blot
The Western blot analysis was performed according to our previously described procedures. 27 Briefly, tumours were carefully dissected from Tgfbr1/Pten 2cKO mice and lysed in a T-PER buffer containing 1% phosphatase inhibitors and complete mini cocktail (Roche). About 40 lg of protein from each sample was denatured and then loaded in each lane of NuPAGE 4-12% Bis-Tris precast gel. Subsequently, proteins were transferred onto a PVDF membrane and blocked with milk for 1 hrs, then incubated with primary antibodies overnight. On Day 2, the membrane was incubated with horseradish peroxidase-conjugated secondary antibody (Pierce, Rockford, IL). The blotting was visualized by an enhanced chemiluminescence kit (West Pico, Thermo). The following primary antibody dilutions were used: 1:1,000 for Notch1, HES1, CCL2 (Cell signaling Technology) and CXCL1 (Abcam) were detected on the same membrane. GAPDH (Cell Signaling Technology) was used as a loading control.
Human HNSCC samples
HNSCC specimens were obtained from the patients in the Hospital of Stomatology of Wuhan University. The pathological analysis was performed by two independent pathologists of the Department of Oral Pathology, Wuhan University. All the HNSCC specimens were made into human HNSCC tissue array, including 97 primary HNSCC cases (Outdo Biotech, Shanghai). The custom made human HNSCC tissue microarrays were used in this study as described previously. 28 The study was performed with the approval of the Institutional Medical Ethics Committee of School and Hospital of Stomatology, Wuhan University (2014LUNSHENZI06, 2016LUNSHENZI62).
Immunochemistry, images analyses and scoring system
Tumours and control tissues such as tongue mucosa were carefully dissected from the mice and fixed in 10% buffered formalin overnight. The tissues were embedded in paraffin. The sections of tissues were deparaffinized, rehydrated and subjected to antigen retrieval by sodium citrate (pH 6.0) or ethylene diamine tetraacetic acid (EDTA) for 20 min. Endogenous peroxidase activity was blocked with 3% H 2 O 2 followed by serum block. The sections were incubated with primary antibodies overnight. On the second day, the sections were reacted with appropriated secondary antibodies. The staining was performed by ABC kits (Vector). The following antibodies were used in this study: Notch1, HES1, PD1, TIM3 (Cell Signaling Technology), LAG3 (Abcam), CTLA4 (Santa Cruz). All immunohistochemically stained slides were scanned using an Aperio ScanScope CS scanner (Vista, CA). Percent positivity (total number of positive pixels/total number of pixel) of whole section were quantified using Aperio ScanScope quantification software (Version 9.1). Area of interest was selected either in the epithelial or the stromal area for quantification. The histoscore of calculated value as a percentage of different percent positive cells were performed using the formula (31) 3 3 1 (21) 3 2 1 (11) 3 1 as previously described. 24 The threshold for scanning of different positive cells was set according to the standard controls slices provided by Aperio.
Statistical analysis
Statistical data analysis was performed with GraphPad Prism 5.03 (GraphPad Software, La Jolla, CA) statistical packages. The resulting data among each group were analyzed through One-way ANOVA, followed by the post-Tukey multiple comparison tests or unpaired t test. Two-tailed Pearson statistical analyses were used for correlated expression of these markers. Mean values 6 SEM with a difference of p < 0.05 were considered statistically significant (ns, p > 0.05; *p < 0.05; **p < 0.01; ***p < 0.001).
Results
Activation of Notch1 signaling in a Tgfbr1/Pten 2cKO mouse model
Our previous study showed that Notch1/HES1 signaling was activated in human HNSCC tissues and cell lines. 20 However,
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there is still a lack of preclinical research on the role of Notch1 signaling in the HNSCC tumour environment. Conditional knockout of Pten and Tgfbr1 in head and neck epithelia of immunocompetent mice using a CK-14Cre-Loxp system gives rise to the initiation and progression of HNSCC through tamoxifen induction. 29 This Tgfbr1/Pten 2cKO mouse model shows full penetration and fast tumour formation and is suitable for therapeutic intervention, especially using immunotherapy. To determine whether Notch1 signaling is activated or down-regulated in the Tgfbr1/Pten 2cKO mouse model, we examined the protein levels of Notch1 signaling in tongue mucosa from wild-type (WT) mice and 2cKO mice and HNSCC tissue from 2cKO mice. The immunohistochemical (IHC) staining and Western blot analysis showed that Notch1 and HES1, which is a putative downstream target of Notch1, were strongly expressed in Tgfbr1/ Pten 2cKO mouse tongue squamous cell carcinoma (TSCC) compared to WT tongue and Tgfbr1/Pten 2cKO mouse tongue (Figs. 1a and 1b) . These results indicate that Notch1 signaling is potentially involved in the development of HNSCC, and pharmacological intervention of Notch1 signaling in vivo in this transgenic mouse model will reveal the action of Notch1/HES1 in HNSCC.
Inhibition of Notch1 signaling reduces tumourigenesis in a Tgfbr1/Pten 2cKO mouse model
To functionally assess the effect of Notch1 signaling on HNSCC progression, we performed a chemopreventive experimental therapeutic investigation on tumour-bearing Tgfbr1/ Pten 2cKO mice. DAPT, a novel g-secretase inhibitor, which prevents proteolytic processing of Notch receptors, 30 was used in this preclinical study. As shown in Figure 2a , conditional knock-out of Tgfbr1 and Pten in epithelia was initiated by oral gavage with tamoxifen (2 mg/kg) for 5 consecutive days. Mice were treated with DAPT (10 mg/kg) or vehicle (100 ml) administered intraperitoneally every day starting at Day 21 after tamoxifen induction. The results of this treatment indicate that tumour volume was remarkably reduced after 3-weeks of DAPT treatment compared with the control group (Figs. 2b and 2c; p < 0.01 on Day 36, p < 0.001 on Days 39 and 42).
Considering the adverse effects of DAPT on the digestive system, 31 we assessed the toxicity of DAPT by examining changes in body weight. No statistical significance was observed between the DAPT-treated group and the control group (Fig.  2d) , which indicates that 10 mg/kg DAPT treatment was well tolerated by the transgenic mice. Likewise, as shown in Figure  2e , the on-target inhibition of Notch1 signaling was confirmed by Western blot, which indicated that Notch1 and HES1 were significantly decreased by the DAPT treatment. Taken together, these results demonstrate that inhibition of Notch1 signaling by DAPT suppressed HNSCC progression.
Effect of DAPT on immunosuppression in an HNSCC mouse model
Notch signaling reportedly has diverse functions in the crosstalk between cancer-associated cells in the tumour microenvironment, 3, 5, 32 participating in multiple immune responses. [33] [34] [35] Our previous findings indicated that tumour-bearing Tgfbr1/ Pten 2cKO mice were in an immunosuppressive state, with increased MDSCs, TAMs and Tregs. 26 Therefore, we explored the potential effect of Notch1 signaling inhibition on these immunosuppressive cells using flow cytometry. First, we found that CD11b (Figs. 4d and 4e ). Taken together, these results suggested that DAPT is effective in reducing the number of immunosuppressive cells in the transgenic mouse model and that it showed different levels of efficacy in different immune organs.
Effect of DAPT on immune checkpoints in an HNSCC mouse model
Immune-checkpoint pathways are a major mechanism of immune resistance, and blockade of these immune checkpoints can enhance the activation of antitumour immune responses. 12 Based on the findings reported above, we investigated whether DAPT has an effect on anti-tumour immune modulation. To determine the effect of DAPT on immune checkpoints in the Tgfbr1/Pten 2cKO mouse, we measured the expression of four major checkpoint molecules (PD1, TIM3, CTLA4 and LAG3) on T cells after DAPT treatment in vivo. Of interest, the results indicated that PD1, TIM3, CTLA4 and LAG3 expression on circulating T cells was decreased by DAPT treatment (Figs. 5a-d) . Consistent with the flow cytometry results, these findings were further substantiated by IHC analysis, which indicated that the checkpoint molecules in the tumour microenvironment were remarkably reduced or diminished in HNSCC tissues in the mouse model after DAPT treatment (Fig. 5e) . And we also analyzed the populations of CD8
1 IFN-g 1 T cells in spleen and tumour microenvironment to investigate the immune activation. The results demonstrated that DAPT treatment can significantly increase CD8 1 IFN-g 1 T cells in the spleen and tumour (Fig. 5f ). Collectively, these observations suggest that DAPT 
Notch1 signaling is associated with immunosuppressive cells markers and immune checkpoints molecules in human HNSCC
Given the effect of DAPT on immunosuppression in the mouse model, we determined the relationship between Notch1 signaling and immunosuppressive cells in human tissues. We quantified the expression of Notch1, Foxp3, PD1, TIM3, CTLA4, LAG3 and of MDSCs markers (CD11b and CD33) and TAMs markers (CD163 and CD68) in 97 primary HNSCC patients using IHC on serial tissue microarrays (Fig.  6a) . The results indicate that the protein expression of Notch1 was correlated with TAMs markers (CD68: r 5 0.2839, p 5 0.0048; CD163: r 5 0.4203, p < 0.0001) and 
Discussion
Numerous recent studies have suggested that additional therapeutic agents should be developed to broaden the utility of active drugs and increase the therapeutic efficacy of immunooncology treatment modalities because of the complex immunosuppressive milieu. 36 In this study, our investigations provide translational evidence supporting the hypothesis that blocking Notch1 with a g-secretase inhibitor can decrease the number of immunosuppressive cells to retune the antitumour immune response. Most importantly, we demonstrate that inhibition of Notch1 signaling can reduce the expression of the negative immune checkpoint molecules PD1, CTLA4, TIM3 and LAG3 on effector T cells.
Aberrant biological process and genetic change in HNSCC may correlate with clinical and epidemiologic variables. 37 Through next-generation sequencing and high-throughput molecular profiling, mutation of Notch1 was discovered to be extensive in HNSCC, ranging from approximately 10% in Caucasian to above 50% in the Chinese population. [16] [17] [18] [19] 38, 39 Discrepancies in the potential role of Notch1 mutations may rely on the different mutation spectrum in different cohort studies or population. [16] [17] [18] [19] 38, 39 Recent reports and our previous studies revealed a critical fact to be considered, namely that Notch1 signaling status perhaps is mostly gain-offunction and highly activated in the Asian population, 16, 17 which is profoundly different from the Caucasian population. 18, 19, 38, 39 Activation of the Notch 1 signaling pathway was observed in the transgenic mouse model, which is suitable for studying the role of Notch 1 in HNSCC. Specifically, the transgenic mouse is an immunocompetent model and facilitates research exploring the change in immune status after inhibition of Notch 1 signaling. Although accumulated studies have confirmed that the Notch1 signaling pathway plays vital roles in T cell 21 and myeloid cell expansion, 22, 23 the exact role of Notch in the solid tumour environment is still unclear. Our remarkable Tumor Immunology and Microenvironment results in this study indicate that Notch1 inhibition can reduce the population of MDSCs in the tumour microenvironment. Moreover, our previous studies showed that DAPT decrease the phosphorylation of signal transducer and activator of transcription 3 (STAT3), which plays an important role in myeloid cell expansion and inhibition of maturation. 27, 40 Nonetheless, due to certain limitations of our studies, more investigations are required to confirm the mechanisms of how Notch1 signaling regulates MDSCs in HNSCC. Because haematopoietic cytokines such as IL-6 and VEGF can modulate the expansion and recruitment of MDSCs by regulating Notch signaling, 41 and previous work has revealed that Notch1 pathways are tightly linked with VEGF, which plays a vital roles in angiogenic expansion of the local vasculature in the tumour microenvironment, 23, 42 VEGF has been recognized as a robust chemokine in the recruitment of MDSCs to the tumour environment. 43 With the present data alone, we cannot completely rule out the possibility that Notch1 signaling blockade reduces the recruitment and expansion of MDSCs through other signaling pathways or combinatorial signaling activity as discussed above. Therefore, how Notch1 signaling regulates MDSCs in HNSCC remains an open question and further studies are required to elucidate the detailed regulation mechanisms. In addition, this study also demonstrated that DAPT treatment could reduce the TAMs population in vivo. However, this phenomenon contradicts previous reports that TAMs with forced Notch activation exhibited an M1 phenotype and antitumour activity. 22, 44 It should be noted that Notch signaling could be activated to perform biological functions in cancer cells and tumour microenvironments. The complex crosstalk between tumours and the microenvironment has been recognized as a major contributor to the progression of cancer, 45, 46 which cannot be ignored in this study. The high correlation between the activation of Notch signaling and the infiltration of TAMs in human HNSCC (Fig. 6d) , may indicate the possibility that Notch signaling is involved in the tumour-microenvironment interactions. However, further mechanistic investigations are required to explain this observation.
The rapidly emerging clinical successes of blocking immune checkpoint molecules, such as CTLA4 and PD1, have opened prospects and extended the potential of cancer immunotherapy. [47] [48] [49] Several immune checkpoint molecules such as PD1, CTLA4, LAG3 and TIM3 have been confirmed to be overexpressed in HNSCC patients. However, the modulation and activation of these immune checkpoint molecules are still uncertain. Of particular interest, the present study revealed that Notch1 inhibition by DAPT can reduce PD1, CTLA4, LAG3 and TIM3 in the tumour microenvironment and macroenvironment, which indicated the reinvigoration of effector T cells. Keeping in mind that these results are rather descriptive, a detailed molecular mechanism needs to be worked out in the future.
In summary, our results clearly indicate that targeting Notch signaling in a Tgfbr1/Pten 2cKO mouse model decreased the number of immunosuppressive cells, and reduced the expression of negative immune checkpoint molecules on T cells in the HNSCC tumour microenvironment and macro-environment. Over-expression of Notch1/HES1 in human HNSCC may be correlated with immunosuppressive cells markers and immune checkpoint molecules. Most importantly, our study points to Notch1 as a potential immunotherapeutic target for treatment of HNSCC patients.
